The speaker will discuss how AstraZeneca R&D IT addresses the rapid evolution and challenges of cell therapy research and development, including key considerations and short-term and long-term strategic foci.

Recently, Adeno-Associated Virus (AAV) entities with associated properties and genealogy, as well as assay results are seamlessly integrated to our data warehouse BDS, facilitating the data management and querying in D360 platform. It enhances the accuracy and efficiency of the AAV research and development processes, and accelerates advancements in cell and gene therapy. In addition, we successfully integrated in vivo studies, complementing the existing in vitro data in D360 platform to enable more informed decision- making for drug discovery projects, establishing the integrated platform for Roche R&D project portfolio across various modalities (i.e., small molecule, oligo, biologics, cell and gene therapy).

Sanofi recently launched the BioAIM program to push forward on our ambition to transform biologics drug discovery. This talk will discuss the landscape of opportunities for ML and AI in all aspects of antibody generation to design and engineering of advanced modalities, our approach, examples of novel methods developed, and early results.

As data science teams grow, balancing consistency with creative innovation becomes crucial. Drawing from my experience building data science teams at Moderna, I'll share how thoughtfully designed workflows enhance creativity by providing stable foundations. We'll explore practical strategies for standardizing project initialization and delivery patterns while preserving scientists' freedom to solve problems their way, using modern tools like pixi and uv to make good practices the path of least resistance.

Understand how computational methods can utilize large and varied datasets to make in silico predictions for optimal design and enhancement of biologics. Learn how recent progress in AI and machine learning has enhanced the ability to mine data for insights related to biologics drug discovery. Explore the opportunities and challenges presented by deep learning techniques in the design and optimization of innovative biologics therapeutics.

As Kite Pharma advances cell therapy to solid tumors and autoimmune diseases, advanced imaging technologies are invested in CAR T discovery. Kite Pharma is collaborating with NVIDIA and Deloitte to explore accelerated streaming of multi-terabyte images to cloud with optimized storage, automated cell segmentation analysis on MONAI with foundation models, integration within image modalities and among diverse modalities (clinical, genomics, and imaging), and GenAI-augmented image meta-data indexing and exploration.

As an R&D organization, Johnson & Johnson Innovative Medicine Data Science & Digital Health is collaborating with the oncology teams to develop an integrated solution for advanced analysis across modalities and scales in CAR T research. Access to multimodality data will enable the utilization of advanced AI/ML technology to enhance our understanding of manufacturability, efficacy, and safety in cell therapy products.

Discover how we transformed lab operations by developing an in-house workflow management and predictive scheduling system. Our solution automates the end-to-end process from request to results, integrating tightly with our data platform, informatics tools, and automation. By tracking progress, supporting task handoffs, and optimizing resource allocation, we enhanced efficiency and visibility across the lab. Learn how predictive resource scheduling answers critical questions about timing and workload management.

Digital transformation, the accelerating pace of scientific and technological advancement as well as increasingly sophisticated analytics and computational methods are putting intense pressure on delivering digital solutions in biotherapeutics research and development. We'll discuss AbbVie's work in this space over the last decade to share lessons learned, discuss challenges and opportunities, and share our vision of a digitally enabled and data-driven biotherapeutics organization to meet the challenges of tomorrow's biopharma landscape.